Back to Library
Peptide Library / Detail
Tirz GLP-2
Dual GIP and GLP-1 Receptor AgonistResearch use only
Half-life
5 days
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Tirzepatide is a novel investigational peptide that acts as a dual agonist of GIP and GLP-1 receptors, enhancing insulin secretion and improving glycemic control while reducing appetite.
Usage
Primarily studied in the treatment of Type 2 diabetes and obesity. Research also explores its cardiovascular and metabolic benefits.
Mechanism of Action
Activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to regulate blood sugar and appetite.
Benefits(4)
- Improved insulin sensitivity
- Appetite suppression
- Significant weight loss
- Better glycemic control
Side Effects(4)
- Nausea
- Vomiting
- Constipation
- Fatigue (in early dosing phase)